A public meeting next month will focus on “scientific data and information about products containing cannabis or cannabis-derived compounds.”
From California to New York, state regulators and the FDA are pushing back against this major trend. Do they have the muscle?
An important finding may not be delivered in time for key UN commission’s vote this March.
Cannabis Wire explores what hemp legalization means for the crop and its products, and the questions still facing Congress and federal regulators.
Until now, only synthetic cannabinoid-based medicines have been approved